Scarica l'app Stockscreener
89.03
0.87%
0.755
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALC Giù?
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$88.28
Aprire:
$87.77
Volume 24 ore:
769.19K
Relative Volume:
0.46
Capitalizzazione di mercato:
$44.00B
Reddito:
$9.93B
Utile/perdita netta:
$1.12B
Rapporto P/E:
39.57
EPS:
2.25
Flusso di cassa netto:
$1.58B
1 W Prestazione:
+2.10%
1M Prestazione:
+3.61%
6M Prestazione:
+4.89%
1 anno Prestazione:
+1.11%
Intervallo 1D:
$87.65
$89.52
Intervallo di 1 settimana:
$86.94
$89.52
Portata 52W:
$80.48
$101.10
Alcon Inc Stock (ALC) Company Profile
Nome
Alcon Inc
Settore
Industria
Telefono
-
Indirizzo
-
Confronta ALC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALC
Alcon Inc
|
89.07 | 44.00B | 9.93B | 1.12B | 1.58B | 2.25 |
|
ISRG
Intuitive Surgical Inc
|
538.87 | 189.82B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
177.58 | 49.98B | 20.87B | 1.50B | 2.59B | 5.24 |
|
RMD
Resmed Inc
|
256.88 | 37.05B | 5.02B | 1.31B | 1.56B | 8.91 |
|
WST
West Pharmaceutical Services Inc
|
222.04 | 16.36B | 2.90B | 467.20M | 306.90M | 6.37 |
Alcon Inc Stock (ALC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-20 | Downgrade | Deutsche Bank | Buy → Hold |
| 2025-05-14 | Reiterato | BTIG Research | Buy |
| 2025-03-28 | Reiterato | Needham | Buy |
| 2025-03-25 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-01-24 | Reiterato | Needham | Buy |
| 2025-01-10 | Aggiornamento | Redburn Atlantic | Neutral → Buy |
| 2024-12-17 | Reiterato | Needham | Buy |
| 2024-11-12 | Reiterato | Needham | Buy |
| 2024-10-10 | Aggiornamento | Redburn Atlantic | Sell → Neutral |
| 2024-09-10 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-07-15 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2024-05-15 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-04-10 | Iniziato | Goldman | Buy |
| 2024-03-14 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2024-02-06 | Ripresa | KeyBanc Capital Markets | Overweight |
| 2024-01-23 | Iniziato | Bernstein | Outperform |
| 2023-12-18 | Downgrade | Redburn Atlantic | Neutral → Sell |
| 2023-12-12 | Iniziato | Stifel | Buy |
| 2023-12-04 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2023-08-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2023-03-01 | Aggiornamento | Societe Generale | Sell → Hold |
| 2022-12-22 | Iniziato | Mizuho | Buy |
| 2022-11-17 | Downgrade | Societe Generale | Hold → Sell |
| 2022-08-11 | Downgrade | Societe Generale | Buy → Hold |
| 2022-05-13 | Ripresa | Credit Suisse | Outperform |
| 2022-05-12 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2022-04-08 | Iniziato | Needham | Buy |
| 2022-03-11 | Iniziato | BofA Securities | Buy |
| 2022-01-18 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2022-01-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-01 | Iniziato | Oppenheimer | Perform |
| 2021-07-14 | Iniziato | Deutsche Bank | Buy |
| 2021-05-06 | Aggiornamento | Citigroup | Sell → Neutral |
| 2021-03-22 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-11-12 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-07-06 | Downgrade | Citigroup | Neutral → Sell |
| 2020-07-06 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2020-06-16 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-04-08 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-03-26 | Aggiornamento | Argus | Hold → Buy |
| 2020-03-24 | Aggiornamento | Societe Generale | Sell → Hold |
| 2020-03-13 | Aggiornamento | UBS | Neutral → Buy |
| 2020-03-05 | Iniziato | Citigroup | Neutral |
| 2020-02-26 | Aggiornamento | Berenberg | Hold → Buy |
| 2020-01-08 | Iniziato | Argus | Hold |
| 2019-10-29 | Iniziato | Stephens | Equal-Weight |
| 2019-08-21 | Reiterato | BofA/Merrill | Neutral |
| 2019-06-24 | Iniziato | SVB Leerink | Mkt Perform |
| 2019-06-14 | Iniziato | BTIG Research | Neutral |
| 2019-05-10 | Iniziato | Robert W. Baird | Outperform |
| 2019-05-02 | Iniziato | Credit Suisse | Outperform |
Mostra tutto
Alcon Inc Borsa (ALC) Ultime notizie
Alcon and Merit Medical: Creating Regulatory and Quality Business Value with AI - Veeva
Should Weakness in Alcon Inc.'s (VTX:ALC) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials? - simplywall.st
Alcon Gets First FDA Approval Since Novartis Spinoff - Orange County Business Journal
Alcon’s Tryptyr Adds Growth, But Valuation Keeps Shares On 'Hold' (NYSE:ALC) - Seeking Alpha
Alcon Stock Rated Buy by BTIG Following TRYPTYR Approval - MSN
Phacoemulsification Devices Market Is Booming Worldwide - openPR.com
Alcon: Achieving UDI Compliance with Veeva RIM - Veeva
Alcon (ALC) Receives Increased Price Target from Citi | ALC Stoc - GuruFocus
Alcon (ALC) Receives Increased Price Target from Citi | ALC Stock News - GuruFocus
Citi more constructive on EU MedTech: Upgrades Demant; Alcon top pick - Investing.com Canada
Alcon Inc. (ALC)’s TRYPTYR Wins FDA Nod for Dry Eye Disease - MSN
BofA Securities lowers Alcon stock price target after Q1 results By Investing.com - Investing.com South Africa
BofA Securities lowers Alcon stock price target after Q1 results - Investing.com Australia
Refractive Surgery Market Is Booming So Rapidly 2025-2032 - openPR.com
Alcon up 4% as FDA approves Tryptyr drops for dry eye - MSN
Citi maintains Buy on Alcon, price target CHF99 after FDA nod - Investing.com Nigeria
Alcon gains FDA approval of Tryptyr in DED - The Pharma Letter
BTIG maintains Alcon $99 target, upbeat on TRYPTYR launch By Investing.com - Investing.com Canada
Citi maintains Buy on Alcon, price target CHF99 after FDA nod By Investing.com - Investing.com South Africa
FDA Approves Alcon’s Tryptyr for Dry Eye Disease - Managed Healthcare Executive
Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019 - Benzinga
Alcon Stock Rises Following the FDA Approval of TRYPTYR - MSN
US FDA approves Alcon's new dry-eye drug - Reuters
FDA approves Alcon’s Tryptyr (AR-15512) for signs and symptoms of dry eye disease - Ophthalmology Times
Alcon receives FDA approval for Tryptyr to treat dry eye disease - World Pharmaceutical Frontiers
FDA approves Alcon’s TRYPTYR for Dry Eye Disease treatment By Investing.com - Investing.com South Africa
BTIG maintains Alcon $99 target, upbeat on TRYPTYR launch - Investing.com
Alcon’s Strategic Initiatives and Valuation Justify Buy Rating with $99 Price Target - TipRanks
US FDA Approves Alcon's Dry Eye Disease Treatment - marketscreener.com
US FDA approves Alcon’s new dry-eye drug - The Mighty 790 KFGO
Alcon (ALC) Gains FDA Approval for Innovative Dry Eye Treatment - GuruFocus
US FDA approves Alcon's new dry-eye drug (May 28) - marketscreener.com
Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic s - GuruFocus
Alcon (ALC) Gains FDA Nod for Innovative Dry Eye Treatment | ALC Stock News - GuruFocus
Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease | ALC Stock News - GuruFocus
FDA approves Alcon’s TRYPTYR for Dry Eye Disease treatment - Investing.com
Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease - marketscreener.com
Gordon Schanzlin New Vision Institute First in Region to Offer Groundbreaking Alcon Sitemap Technology for Personalized Vision Correction - GlobeNewswire Inc.
BTIG maintains Alcon stock Buy rating, $99 target By Investing.com - Investing.com South Africa
DOJ Requires Keysight to Shed Spirent Units Before $1.57 Billion Acquisition Proceeds - PYMNTS.com
BTIG maintains Alcon stock Buy rating, $99 target - Investing.com
Alcon Inc Azioni (ALC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.10%
0.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):